BIOCERA MEDICAL LIMITED

What BIOCERA MEDICAL LIMITED does

BioCera Medical Limited is a UK-based, privately-held medical device technology company founded in January 2020. The company develops and holds intellectual property in an Electro Chemical Oxidation (ECO) process that builds bioceramic surface layers on medical implant-grade metal substrates (Magnesium, Titanium, and Zirconium alloys). BioCera is headquartered in Haverhill, Suffolk (3b Homefield Road, CB9 8QP) and is owned entirely by its founders, an international team of medical and material scientists, medical doctors, and technology entrepreneurs specialised in implants and surface treatments.

The company's core product line comprises three ECO bioceramic coatings: a three-layered nanoceramic coating for titanium alloys that prevents metal ion release, enhances osseointegration, and provides a bone-like white colour; a dense bioceramic coating for magnesium alloys that controls resorption rate and incorporates antibacterial elements (Zn, Cu, Ga, Sr, Si, S, Ag, Zr); and an analogous coating for zirconium alloys. Underlying the platform is a patented electrochemical oxidation process (PCT WO 2020049299) that combines surface oxidation with co-deposition of selected elements from an aqueous electrolyte, producing coatings 5-20 microns thick with a growth rate of 1-3 microns per minute. The process is described as environmentally friendly with no hazardous substances and does not require a line-of-sight, enabling treatment of complex 3D printed implant geometries. Quantified performance claims include more than 30x reduction in corrosion rate on AZ31 magnesium (University of Portsmouth, ACS Appl. Bio Mater. 2024) and 65% higher bone-implant contact versus uncoated titanium in vivo.

BioCera operates a B2B technology-provider model, licensing its coating IP and providing surface treatment services to medical implant manufacturers across orthopedic/trauma, dental/craniofacial, and cardiovascular device applications. Pricing is not publicly disclosed and appears to follow a quote-based B2B model. Distribution is direct (no channel intermediaries), and go-to-market is R&D- and relationship-driven through academic collaborations (University of Manchester, University of Portsmouth), scientific conference presentations (European Society for Biomaterials 2023, BioMaH 2022), and downloadable white papers/project reports hosted on the company website. Revenue is not disclosed and the company appears pre-commercial, with funding to date coming from an Innovate UK grant rather than equity investment.

Name

BIOCERA MEDICAL LIMITED

Legal name

BioCera Medical Limited

Website

https://biocera-med.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

BioCera Medical Limited is a UK-based, founder-owned medical device technology company that develops proprietary Electro Chemical Oxidation (ECO) bioceramic coatings for titanium, magnesium, and zirconium alloy implants, licensing its IP and providing coating services to orthopedic, dental, and cardiovascular implant manufacturers.

Ownership category

akta.pro rank

Product category

Medical Device Surface Treatment

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Paint and Coating Manufacturing (32551), Electroplating, Plating, Polishing, Anodizing, and Coloring (332813)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)

akta.pro secondary industry

Implant Prosthetics & Abutment Fabrication (HLABAJAC)

Keywords

• Bioceramic coatings
• Implant surface treatment
• Electrochemical oxidation coatings
• Orthopedic implant coatings
• Magnesium alloy coatings

Headquarters

HQ city

Haverhill

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Bioceramic Surfacing Technology: Developer and IP owner of electrochemical bioceramic coating process for medical implants. Revenue derived from licensing coating technology and providing surface treatment services to medical device manufacturers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BioCera Medical develops and licenses Electro Chemical Oxidation (ECO) technology for applying nanoceramic bioceramic coatings to medical implant surfaces. The company offers specialized coatings for Titanium, Magnesium, and Zirconium alloy implants used in orthopedic, dental, and cardiovascular applications. Revenue is generated primarily through licensing of the patented ECO process and provision of surface treatment services to medical device manufacturers.

Product overview

BioCera Medical offers the ECO (Electro Chemical Oxidation) technology platform for bioceramic surfacing of medical implants. The core product line consists of specialized nanoceramic coatings for Titanium, Magnesium, and Zirconium alloys. The ECO Bioceramic Coating for Titanium provides a three-layered structure with osseointegration benefits and metal ion barrier properties. The ECO Bioceramic Coating for Magnesium addresses the high corrosion rate problem of magnesium alloys through resorption rate control and antibacterial functionality. All coatings are applied using the proprietary electrochemical oxidation process that combines surface oxidation with elemental co-deposition from electrolyte solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• ECO Bioceramic Coating for Titanium A three-layered nanoceramic coating applied to titanium alloy implants via Electro Chemical Oxidation (ECO) process. The coating prevents metal ion (Al, V) release, enhances osseointegration (demonstrated 65% higher bone-implant contact versus uncoated titanium in vivo), provides natural bone-like white colour (30-42% reflectance), and offers scratch/wear resistance. Designed for orthopedic, dental, and craniofacial implant manufacturers using titanium alloys including Ti6Al4V.
• ECO Bioceramic Coating for Magnesium A dense bioceramic coating applied to biodegradable magnesium alloy implants (e.g., AZ31) that controls resorption rate, provides enhanced osseointegration, and incorporates antibacterial elements (Zn, Cu, Ga, Sr, Si, S, Ag, Zr). Demonstrated over 30x reduction in corrosion rate and maintains coating integrity over multiple insertions into bone. Designed for orthopedic, trauma, and resorbable implant manufacturers using magnesium alloys.
• ECO Bioceramic Coating for Zirconium Electro Chemical Oxidation (ECO) technology applied to zirconium alloy implants, extending the company's bioceramic surface treatment capabilities beyond titanium and magnesium. Zirconium alloys are used in specialized medical implant applications requiring enhanced biocompatibility and corrosion resistance.

Quantifiable outcome

• Biocera coating on AZ31 Magnesium reduces corrosion rate more than 30 times
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• University of PortsmouthcoreStrategic or Co-development Partner · 1 January 2022University of Portsmouth conducted characterisation of Biocera coating on Magnesium alloys. Collaborated on Innovate UK-funded project for resorbable magnesium implants. Presented research 'Evaluation of Corrosion Performance of AZ31 Mg Alloy' published in ACS Appl. Bio Mater. 2024.
• University of ManchestercoreStrategic or Co-development Partner · 1 January 2018University of Manchester characterised Biocera coating on Titanium alloys, supported by Innovate UK grant 61320 – 435222. Published project report 'Multifunctional Nanoceramic surfacing for Titanium implants'.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Cam Bioceramics: Manufacturer of calcium phosphate-based bioceramics used as coatings and bone substitute materials for orthopedic and dental implants. Comparable as a bioceramic-focused supplier to the implant industry.
• Medicoat AG: Swiss provider of plasma-sprayed and bioceramic coatings for orthopedic and dental implants. Comparable as a specialty medical implant coating company offering surface treatment services and licensed technology to OEMs.
• Himed: US-based biomaterials company supplying calcium phosphate and bioceramic coatings and powders for medical and dental implants. Directly comparable as a bioceramic surface treatment specialist serving implant OEMs.
• DOT GmbH: German specialist in surface coatings for medical implants, including bioceramic, hydroxyapatite, and electrochemical coatings on titanium and other alloys. Directly comparable as a contract coating partner serving orthopedic and dental implant OEMs with proprietary surface treatment IP.
• Eurocoating S.p.A. Italian provider of surface treatments for orthopedic prostheses and implants, including plasma spray and bioceramic coatings. Comparable as a specialist coating service provider to medical device OEMs.

Broad incumbents

• Orchid Orthopedic Solutions: US-based contract manufacturer of orthopedic implants offering coating and surface treatment services as part of a broader manufacturing portfolio. Comparable as a large incumbent providing coated implant components to OEMs.
• Aap Implantate AG: German orthopedic implant manufacturer with proprietary surface treatment technologies including silver-coated and hydroxyapatite-coated trauma implants. Comparable as an established implant company combining surface coating IP with device manufacturing.

Emerging players

• NanoCoatings (Isoflux): US-based developer of advanced surface coatings for medical implants using novel deposition techniques. Comparable as an emerging peer pursuing next-generation implant surface treatments distinct from conventional plasma spray approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biocera-medical-limited

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOCERA MEDICAL LIMITED